Merrimack's MM-398 gets Priority Review

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) and the Baxalta Inc. subsidiary of Baxter International Inc. (NYSE:BAX) said FDA accepted and granted Priority Review to an NDA for MM-398 as second-line treatment for metastatic pancreatic cancer. Its PDUFA date is Oct. 24.

Also on Thursday, the partners said EMA accepted an MAA for the compound in the same indication. ...